Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2025 Apr 2;19(4):e0012962. doi: 10.1371/journal.pntd.0012962

Clinical presentation of Oropouche virus infection: A systematic review and meta-analysis

Zhilin Wang 1,2,#, Linzhu Huang 1,#, Xinyu Zhang 1, Xinyue Zhang 1, Liwei Huang 1, Xiaoying Zhu 1,3,4, Xidai Long 1,3,4,*, Demin Cao 1,3,4,*, Yulei Li 1,3,4,*
Editor: Adly MM Abd-Alla,5
PMCID: PMC11981143  PMID: 40173204

Abstract

Background

The recent surge in incidence and geographic spread of OROV infections poses an escalating threat to global public health. However, studies exploring the clinical signs of OROV infection remains exceedingly limited.

Methods

We searched for OROV studies published until June 17, 2024, in several electronic databases including MEDLINE, EMBASE, SCOPUS, and the Cochrane Library.

Results

In total, 15 studies involving 806 patients with OROV infection were eligible for inclusion. General symptoms with fever and headache were the most common. Gastrointestinal disturbances like nausea/vomiting, anorexia, and odynophagia were also prevalent, along with ocular symptoms, mainly retro-orbital pain, photophobia, and redness. Respiratory symptoms, such as cough, sore throat and nasal congestion, are present, and skin-related issues like rash, pruritus, and pallor were also identified.

Conclusion

Overall, this study provides a foundational understanding of OROV’s clinical manifestations to guide diagnosis, management, and public health interventions against this neglected tropical disease.

Author summary

In the realm of life sciences, understanding the full scope of infectious diseases is crucial for protecting public health. Oropouche virus (OROV), a relatively under-studied pathogen, has been showing an alarming increase in both incidence and geographical spread recently. Despite its growing threat, our knowledge of the clinical symptoms it causes has been severely lacking. Our study is the first of its kind to comprehensively review and analyze available research on OROV-related symptoms. By pooling 15 studies involving 806 patients, we’ve uncovered a range of symptoms from common fever and headache to less-known ocular, gastrointestinal, and skin - related issues. This new understanding is vital. For scientists, it lays the groundwork for further research into OROV’s biology and disease mechanisms. For non-scientists, it helps in early recognition of the disease, which is key to getting proper medical care and preventing its spread.

Introduction

Oropouche virus (OROV) is an arbovirus member of the Peribunyaviridae family and the Orthobunyavirus genus. Since its first discovery in 1955 in Trinidad and Tobago [1], OROV has recurrently provoked epidemics throughout South and Central American territories [2]. These episodic outbreaks are often linked to midge vector (Culicoides paraensis) with sloths and non-human primates serving as reservoir hosts, primarily occurred in the urban settings of Amazon basin region (like the Brazilian Amazon), where there is often a proliferation of insects [3,4]. However, in recent years, a notable increase in the incidence and geographical spread of reported OROV infections has been observed, highlighting a growing public health concern [5,6]. On February 2, 2024, the Pan American Health Organization (PAHO, WHO) issued an alert about a surge in OROV infection cases in some American countries in recent months [7], sparking concerns that the virus could be the next one to cause a major outbreak in Latin America.

OROV causes an acute febrile disease with diverse clinical manifestations. It often overlaps with common febrile diseases in regions such as dengue fever, Zika virus disease and chikungunya, which brings great challenges to clinical differential diagnosis [8–10]. To date, the comprehensive picture of clinical manifestations resulting from OROV infections remain poorly understood and characterized, as there is an evident lack of systematic reviews. This systematic review aims to summarize available evidence regarding the clinical presentation in OROV infections from available reports and studies.

Methods

Search strategy and data sources

A comprehensive search was performed in several electronic databases including MEDLINE, EMBASE, SCOPUS, and the Cochrane Central Register of Controlled Trials. This systematic search encompassed peer-reviewed studies to ensure the retrieval of high-quality and validated research related to the topic of interest. In addition, the reference lists of the included studies were screened for potentially eligible studies. We used controlled vocabulary supplemented with keywords search terms related to Oropouche virus. Only articles published in English were included in this systematic review. Studies published until June 17, 2024, were included. This meta-analysis study was not registered.

Eligibility criteria

Eligible studies had to meet all of the following inclusion criteria: (1) OROV infections were confirmed by polymerase chain reaction (PCR)or enzyme-linked immunosorbent assay (ELISA), and (2) studies containing detailed descriptions of clinical manifestations. Any observational studies (cohort, case-control, cross-sectional or case series) are included, no matter prospective or retrospective. Exclusion criteria were as follows: (1) Studies with sample sizes smaller than five, (2) studies on non-human hosts, (3) non-original investigations: reviews, meta-analyses, letters, commentaries, editorials, errata, and other articles.

Study selection and data extraction

We used a two-stage screening approach: first by title and abstract and then by full text article. Two researchers independently screened each title, abstract, and full text and resolved discrepancies by consensus with a third researcher. For studies that have met the inclusion criteria, the following data were extracted using an extraction form: (1) author and its publication date, (2) study design, (3) Study period, (4) location of study, (5) baseline characteristics: sample size, age, sex, specimen detection, (6) clinical presentation.

Quality assessment

The risk of bias of each study was independently evaluated by two authors using the methodological quality and synthesis of case series and case reports described by Murad et al [11]. All discrepancies were resolved by the independent opinion of a third reviewer. This article followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (S1 Checklist).

Data analysis

We conducted this meta-analysis on R (version 4.0.3) using the meta and metafor packages. The fixed effect model will be used to derive the pooled prevalence estimates. If the prevalence in a study was reported as zero, we added a continuity correction of 0.5 to the number of cases before statistical analysis [12,13]. Forest plot was used to visualize the proportion of clinical presentation in OROV infections in each study and the overall pooled prevalence estimates. The I2 statistic was used to estimate the level of heterogeneity. An I2 of >75% indicated substantial heterogeneity. The publication bias was qualitatively assessed by visualizing the studies with a funnel plot and Egger’s test.

Results

Study selection and characteristics

The initial search across four electronic databases yielded a total of 574 potentially relevant articles. Following the removal of duplicates and subsequent screening based on titles, abstracts, and full texts, 15 studies [8,14–27] involving 806 OROV-infected patients were eligible for inclusion (Fig 1 and S1 Data). Among the included studies, there were 12 cohort studies, two case series, and one cross-sectional study. All studies were from Latin America, with a maximum of eight from Brazil, five from Peru, and one each from Colombia and French Guiana. Detailed information is presented in Table 1. The sampling dates of the studies were broadly distributed, covering a range that extended from 1999 to 2023.

Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart—showing the literature search strategy and the numbers of peer-reviewed articles included in, and excluded from, this study.

Fig 1

Table 1. Baseline characteristics of OROV-infected patients included in the study.

No Study N Study design Country/ region Age, years mean±SD/
mdeian(IQR)
Sex (man) Specimen detection Study period
1 Aguilar et al. 2011 [14] 16 Cohort Peru NA NA Viral culture; PCR 2003-2006
2 Alva-Urcia et al. 2017 [15] 12 Cross-sectional Peru NA(range 5 to >45 years) 8 PCR January-March 2016
3 Azevedo et al. 2007 [16] 93 Cohort Brazil NA(range 1 to >55 years) 35 HI; ELISA 2003-2004
4 Cardoso et al. 2015 [17] 5 Cohort Brazil NA(range 14 to 62 years) 1 RT-qPCR October 2011-July 2012
5 Carvalho et al. 2022 [18] 39 Cohort Brazil NA NA Viral culture; ELISA January-February 2018
6 Ciuoderis et al. 2022 [19] 105 Cohort Colombian NA(range <18 to >18 years) 55 RT-qPCR 2019-2022
7 da Costa et al. 2017 [20] 6 Cohort Brazil 29.5±7 NA ELISA 2011–2013
8 Gaillet et al. 2021 [21] 23 Case series French Guiana NA(range <18 to >18 years) 14 PCR August–September 2020
9 Martins-Luna et al.2020 [22] 131 Cohort Peru NA(range <5 to >5 years) 72 PCR February-September 2016
10 Moreira et al. 2024 [23] 12 Cohort Brazil 43±17.68 16 RT-qPCR January 2022-March 2023
11 Mourão et al. 2009 [24] 128 Cohort Brazil 29.5±14 51 ELISA January 2007-November 2008
12 Naveca et al. 2018 [25] 9 Case series Brazil 36.2(range 8 to 63 years) 7 PCR April-June 2015
13 Silva-Caso et al. 2019 [26] 46 Cohort Peru 22.3±15.6 25 PCR January-July 2016
14 Vasconcelos et al. 2009 [27] 113 Cohort Brazil NA(range 0 to >55 years) 49 HI; ELISA; Viral culture; PCR May-June 2006
15 Watts et al. 2022 [8] 68 Cohort Peru 31(range 1 to >44 years) 44 Viral culture; ELISA 1993-1999

Abbreviations: ELISA, enzyme linked immunosorbent assay; HI, hemagglutination inhibition; NA, not applicable; PCR, polymerase chain reaction; RT-qPCR, quantitative reverse transcription polymerase chain reaction; SD, standard deviation.

Quality assessment

The quality assessment results of all included studies are shown in Table 2. Only one study was of poor quality, all the remaining studies were judged to be of good quality, and these patients appeared to be representative of the full range of investigator experiences, where exposures and outcomes were adequately determined, and where follow-up was long enough.

Table 2. Methodological quality assessment tool results.

Study Question 1 Question 2 Question 3 Question 4 Question 5
Aguilar et al. 2011 [14] Yes Yes Yes Yes Yes
Alva-Urcia et al. 2017 [15] Yes Yes Yes Yes Yes
Azevedo et al. 2007 [16] Yes Yes Yes Yes Yes
Cardoso et al. 2015 [17] Yes Yes Yes Yes Yes
Carvalho et al. 2022 [18] Yes Yes Yes No Yes
Ciuoderis et al. 2022 [19] Yes Yes Yes Yes Yes
da Costa et al. 2017 [20] Yes Yes Yes Yes Yes
Gaillet et al. 2021 [21] Yes Yes Yes Yes Yes
Martins-Luna et al.2020 [22] Yes Yes Yes Yes Yes
Moreira et al. 2024 [23] Yes Yes Yes Yes Yes
Mourão et al. 2009 [24] Yes Yes Yes No No
Naveca et al. 2018 [25] No Yes Yes No No
Silva-Caso et al. 2019 [26] Yes Yes Yes Yes Yes
Vasconcelos et al. 2009 [27] Yes Yes Yes Yes Yes
Watts et al. 2022 [8] Yes Yes Yes Yes Yes

Question 1: Does the patient(s) represent(s) the whole experience of the investigator (center)?

Question 2: Was the exposure adequately ascertained?

Question 3: Was the outcome adequately ascertained?

Question 4: Was follow-up long enough for outcomes to occur?

Question 5: Is the case(s) described with sufficient detail to allow other investigators to replicate the research or to allow practitioners make inferences related to their own practice?

General symptoms

All studies included in this systematic review reported general symptoms of fever and headache. Other general symptoms reported included myalgia (14 studies), arthralgia (14 studies), chills (seven studies), dizziness (five studies), weakness/fatigue (five studies), and neck/back pain (five studies). The overall pooled prevalence for fever, headache, myalgia, arthralgia, chills, dizziness, weakness/fatigue, and neck/back pain were 100% (95% confidence interval [CI] 99%-100%), 95% (95% CI 94%-96%), 72%(95% CI 69%-75%), 58% (95% CI 55%-61%), 26%(95% CI 21%-31%), 69%(95% CI 66%-73%), 45%(95% CI 40%-51%), 48%(95% CI 43%-52%), respectively (Figs 2 and 3). All general symptoms but fever (I2 = 0%) were heterogeneous among studies, with I2 ranging from 85%–98%.

Fig 2. Pooled prevalence of general symptoms in OROV-infected patients.

Fig 2

Fig 3. Pooled prevalence of general symptoms in OROV-infected patients.

Fig 3

Gastrointestinal symptoms

Gastrointestinal symptoms in patients with OROV infection included in this study included nausea/vomit (12 studies), abdominal pain (nine studies), diarrhea (seven studies), anorexia (six studies), odynophagia (four studies), and jaundice (two studies). The overall pooled prevalence of anorexia was the highest (59%, 95% CI 53%-64%), followed by nausea/vomit (44% 95% CI 40%-48%), odynophagia (26%, 95% CI 21%-31%), diarrhea (17%, 95% CI 12%-21%), jaundice(10%, 95% CI 0%-24%), and abdominal pain(7%, 95% CI 5%-9%) (Fig 4). Aside from diarrhea and jaundice, other gastrointestinal symptoms exhibited heterogeneity across studies, ranging from 75% to 91%.

Fig 4. Pooled prevalence of gastrointestinal symptoms in OROV-infected patients.

Fig 4

Ocular symptoms

In all studies included, ocular involvement was manifested as retro-orbital pain (13 studies), photophobia (two studies), and redness (one studies). Among them, retro-orbital pain was the most common (56%, 95% CI 52%-61%), followed by photophobia (31%, 95% CI 23%-38%) and red eyes (27%, 95% CI 19%-36%) (Fig 5).

Fig 5. Pooled prevalence of ocular symptoms in OROV-infected patients.

Fig 5

Respiratory symptoms

Patients infected with OROV primarily present with four respiratory symptoms, typically manifesting as cough (14%, 95% CI 7%-21%), sore throat (15%, 95% CI 9%-21%), and nasal congestion (15%, 95% CI 8%-23%), while the symptom of respiratory distress/dyspnea is less common (1%, 95% CI 0%-2%) (Fig 6).

Fig 6. Pooled prevalence of respiratory symptoms in OROV-infected patients.

Fig 6

Skin-related symptoms

OROV infection also caused skin-related symptoms, including rash, pruritus, and pallor, with the highest overall pooled prevalence of pallor (28%, 95% CI 12%-44%), followed by pruritus (12%, 95% CI 3%-21%) and rash (11%, 95% CI 9%-14%) (Fig 7).

Fig 7. Pooled prevalence of skin-related symptoms in OROV-infected patients.

Fig 7

Discussion

This systematic review is the first to explore pooled prevalence of clinical features and complications of OROV infection.

Fever and headache are common symptoms in individuals infected with OROV, with overall prevalence rates of 100% and 95% respectively, compared to a higher prevalence observed in dengue fever infections [28]. However, this difference should be interpreted cautiously, as the current scarcity of epidemiological monitoring studies on OROV, with many research efforts focused solely on patients exhibiting clinical fever but testing negative for dengue, may lead to an overestimation of these symptoms’ prevalence due to selection bias. The overall pooled prevalence of myalgia, joint pain and chills is comparable to dengue and Zika infections [28,29].

OROV infections are commonly associated with gastrointestinal symptoms, including anorexia, nausea/vomit, odynophagia, diarrhea, and abdominal pain. These symptoms show similarities with those observed in dengue fever infections [29]. Moreover, the observation of jaundice in two of our studies indicates that the viral infection may lead to hemolysis or liver injury in certain cases. The prominence of ocular involvement, particularly retro-orbital pain, photophobia, and red eyes. Ophthalmologic evaluations should be integrated into the management protocol for suspected OROV cases to ensure timely intervention and reduce the risk of ocular complications. Respiratory symptoms, including cough, sore throat, and nasal congestion, and occur in a minority of OROV patients, with prevalences ranging from 14% to 15%. The infrequent occurrence of respiratory distress (1%) suggests that severe pulmonary complications are uncommon, distinguishing OROV from respiratory viruses like influenza and SARS-CoV-2 [30,31]. Notably, rash occurs in only 11% of OROV infections, significantly lower than in dengue fever and Zika virus infections [29,32].

This review has several limitations. The main limitation is that the included studies were mostly retrospective studies and lacked high-quality data. Additionally, patients who were asymptomatic or had mild cases and who did not require hospitalization were not accounted for due to publication bias. The systematic review may also have missed studies that were not indexed or published in local journals, especially in languages other than English.

Conclusion

In conclusion, the multi-systemic nature of OROV infections, as revealed by this systematic review, calls for a heightened clinical awareness and a comprehensive approach to patient evaluation. By recognizing the breadth of symptoms associated with OROV, healthcare providers can more accurately diagnose and manage this infection, thereby contributing to better health outcomes and facilitating the development of targeted therapeutic interventions.

Supporting information

S1 Data. Original data of OROV-infected patients included in the study.

(XLSX)

pntd.0012962.s001.xlsx (18.4KB, xlsx)
S1 Checklist. PRISMA 2020 Checklist.

(DOCX)

pntd.0012962.s002.docx (30.6KB, docx)

Acknowledgments

This study was non-financially supported in by Baise Talent Highland (No. 2020-3-2), Building Projects of Guangxi Bagui Scholars (No. Guirencaiban [2024]-29), Building Projects of the Key Laboratory of Molecular Pathology in Tumor of Guangxi Higher Education Institutes (No. Guijiaokeyan [2022]-10), Building Projects of the Key Laboratory of Molecular Pathology in Tumor of Baise (No. 2022), and Clinical Key Specialty Building Project (For Pathology) of Guangxi (No. Guiweiyifa [2022]-21).

Data Availability

All relevant data are in the manuscript and its supporting information files.

Funding Statement

This study was supported in by Joint Special project of Guangxi Natural Science Foundation (2025GXNSFHA069143 to Y.L.;2025GXNSFHA069078 to D.C.). The funders had no role in study design, data collection, and interpretation, or submitting the work for publication.

References

  • 1.Anderson CR, Spence L, Downs WG, Aitken TH. Oropouche virus: a new human disease agent from Trinidad, West Indies. Am J Trop Med Hyg. 1961;10:574–8. [DOI] [PubMed] [Google Scholar]
  • 2.Romero-Alvarez D, Escobar LE. Oropouche fever, an emergent disease from the Americas. Microbes Infect. 2018;20(3):135–46. doi: 10.1016/j.micinf.2017.11.013 [DOI] [PubMed] [Google Scholar]
  • 3.Wesselmann KM, Postigo-Hidalgo I, Pezzi L, de Oliveira-Filho EF, Fischer C, de Lamballerie X, et al. Emergence of Oropouche fever in Latin America: a narrative review. Lancet Infect Dis. 2024;24(7):e439–52. doi: 10.1016/S1473-3099(23)00740-5 [DOI] [PubMed] [Google Scholar]
  • 4.Sciancalepore S, Schneider MC, Kim J, Galan DI, Riviere-Cinnamond A. Presence and multi-species spatial distribution of Oropouche virus in Brazil within the one health framework. Trop Med Infect Dis. 2022;7(6):111. doi: 10.3390/tropicalmed7060111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Zhang Y, Liu X, Wu Z, Feng S, Lu K, Zhu W, et al. Oropouche virus: a neglected global arboviral threat. Virus Res. 2024;341:199318. doi: 10.1016/j.virusres.2024.199318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mohapatra RK, Mishra S, Satapathy P, Kandi V, Tuglo LS. Surging Oropouche virus (OROV) cases in the Americas: a public health challenge. New Microbes New Infect. 2024;59:101243. doi: 10.1016/j.nmni.2024.101243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.PAHO Public health risk assessment related to Oropouche virus (OROV) in the region of the Americas; 2024. [Google Scholar]
  • 8.Watts DM, Russell KL, Wooster MT, Sharp TW, Morrison AC, Kochel TJ, et al. Etiologies of acute undifferentiated febrile illnesses in and near Iquitos from 1993 to 1999 in the Amazon River Basin of Peru. Am J Trop Med Hyg. 2022;107(5):1114–28. doi: 10.4269/ajtmh.22-0259 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fonseca LMDS, Carvalho RH, Bandeira AC, Sardi SI, Campos GS. Oropouche virus detection in febrile patients’ saliva and urine samples in Salvador, Bahia, Brazil. Jpn J Infect Dis. 2020;73(2):164–5. doi: 10.7883/yoken.JJID.2019.296 [DOI] [PubMed] [Google Scholar]
  • 10.Ricapa-Antay F, Diaz-Melon K, Silva-Caso W, Del Valle LJ, Aguilar-Luis MA, Vasquez-Achaya F, et al. Molecular detection and clinical characteristics of Bartonella bacilliformis, Leptospira spp., and Rickettsia spp. in the Southeastern Peruvian Amazon basin. BMC Infect Dis. 2018;18(1):618. doi: 10.1186/s12879-018-3541-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–3. doi: 10.1136/bmjebm-2017-110853 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pace NL. Research methods for meta-analyses. Best Pract Res Clin Anaesthesiol. 2011;25(4):523–33. doi: 10.1016/j.bpa.2011.08.005 [DOI] [PubMed] [Google Scholar]
  • 13.Pang Y, Lu H, Cao D, Zhu X, Long Q, Tian F, et al. Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis. BMC Public Health. 2024;24(1):1244. doi: 10.1186/s12889-024-18748-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Aguilar PV, Barrett AD, Saeed MF, Watts DM, Russell K, Guevara C, et al. Iquitos virus: a novel reassortant Orthobunyavirus associated with human illness in Peru. PLoS Negl Trop Dis. 2011;5(9):e1315. doi: 10.1371/journal.pntd.0001315 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Alva-Urcia C, Aguilar-Luis MA, Palomares-Reyes C, Silva-Caso W, Suarez-Ognio L, Weilg P, et al. Emerging and reemerging arboviruses: a new threat in Eastern Peru. PLoS One. 2017;12(11):e0187897. doi: 10.1371/journal.pone.0187897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Azevedo RS, Nunes MR, Chiang JO, Bensabath G, Vasconcelos HB, Pinto AY, et al. Reemergence of Oropouche fever, northern Brazil. Emerg Infect Dis. 2007;13(6):912–5. doi: 10.3201/eid1306.061114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cardoso BF, Serra OP, Heinen LB, Zuchi N, Souza VC, Naveca FG, et al. Detection of Oropouche virus segment S in patients and inCulex quinquefasciatus in the state of Mato Grosso, Brazil. Mem Inst Oswaldo Cruz. 2015;110(6):745–54. doi: 10.1590/0074-02760150123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Carvalho VL, Azevedo RSS, Carvalho VL, Azevedo RS, Henriques DF, Cruz ACR, et al. Arbovirus outbreak in a rural region of the Brazilian Amazon. J Clin Virol. 2022;150–151:105155. doi: 10.1016/j.jcv.2022.105155 [DOI] [PubMed] [Google Scholar]
  • 19.Ciuoderis KA, Berg MG, Perez LJ, Hadji A, Perez-Restrepo LS, Aristizabal LC, et al. Oropouche virus as an emerging cause of acute febrile illness in Colombia. Emerg Microbes Infect. 2022;11(1):2645–57. doi: 10.1080/22221751.2022.2136536 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.da Costa VG, de Rezende Féres VC, Saivish MV, de Lima Gimaque JB, Moreli ML. Silent emergence of Mayaro and Oropouche viruses in humans in Central Brazil. Int J Infect Dis. 2017;62:84–5. doi: 10.1016/j.ijid.2017.07.016 [DOI] [PubMed] [Google Scholar]
  • 21.Gaillet M, Pichard C, Restrepo J, Lavergne A, Perez L, Enfissi A, et al. Outbreak of Oropouche virus in French guiana. Emerg Infect Dis. 2021;27(10):2711–4. doi: 10.3201/eid2710.204760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Martins-Luna J, Del Valle-Mendoza J, Silva-Caso W, Sandoval I, Del Valle LJ, Palomares-Reyes C, et al. Oropouche infection a neglected arbovirus in patients with acute febrile illness from the Peruvian coast. BMC Res Notes. 2020;13(1):67. doi: 10.1186/s13104-020-4937-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Moreira HM, Sgorlon G, Queiroz JAS, Roca TP, Ribeiro J, Teixeira KS, et al. Outbreak of Oropouche virus in frontier regions in western Amazon. Microbiol Spectr. 2024;12(3):e0162923. doi: 10.1128/spectrum.01629-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mourão M, Bastos M, Gimaque J, Mota B, Souza G, Grimmer G. Oropouche fever outbreak, Manaus, Brazil, 2007-2008. Emerg Infect Dis. 2009;15(12):2063–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Naveca FG, Nascimento VA, Souza VC, de Figueiredo RMP. Human Orthobunyavirus infections, Tefé, Amazonas, Brazil. PLoS Curr. 2018;10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Silva-Caso W, Aguilar-Luis MA, Palomares-Reyes C, Mazulis F, Weilg C, Del Valle LJ, et al. First outbreak of Oropouche Fever reported in a non-endemic western region of the Peruvian Amazon: Molecular diagnosis and clinical characteristics. Int J Infect Dis. 2019;83:139–44. doi: 10.1016/j.ijid.2019.04.011 [DOI] [PubMed] [Google Scholar]
  • 27.Vasconcelos HB, Azevedo RSS, Casseb SM, Nunes-Neto JP, Chiang JO, Cantuária PC, et al. Oropouche fever epidemic in Northern Brazil: epidemiology and molecular characterization of isolates. J Clin Virol. 2009;44(2):129–33. doi: 10.1016/j.jcv.2008.11.006 [DOI] [PubMed] [Google Scholar]
  • 28.Guo C, Zhou Z, Wen Z, Liu Y, Zeng C, Xiao D, et al. Global epidemiology of dengue outbreaks in 1990-2015: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2017;7:317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kharwadkar S, Herath N. Clinical manifestations of dengue, Zika and chikungunya in the Pacific Islands: a systematic review and meta-analysis. Rev Med Virol. 2024;34(2):e2521. doi: 10.1002/rmv.2521 [DOI] [PubMed] [Google Scholar]
  • 30.Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436. doi: 10.1136/bmj.n436 [DOI] [PubMed] [Google Scholar]
  • 31.Uyeki T, Hui D, Zambon M, Wentworth D, Monto A. Influenza. Lancet. 2022;400(10353):693–706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Musso D, Gubler D. Zika virus. Clin Microbiol Rev. 2016;29(3):487–524. [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012962.r002

Decision Letter 0

Elvina Viennet

28 Jan 2025

PNTD-D-24-01266Clinical presentation of Oropouche virus infection: a systematic review and meta-analysisPLOS Neglected Tropical Diseases  Dear Dr. Li, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within 30 days Mar 29 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers '. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes '. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript '. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Adly M.M. Abd-Alla, Prof asso.Academic EditorPLOS Neglected Tropical Diseases

Elvina Viennet

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

Journal Requirements:

1) Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full.

At this stage, the following Authors/Authors require contributions: Yulei Li, Mengxi Gu, Xinyue Zhang, Xiaoying Zhu, Demin Cao, and Xidai Long. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form.

The list of CRediT author contributions may be found here: https://journals.plos.org/plosntds/s/authorship#loc-author-contributions

2) Please provide an Author Summary. This should appear in your manuscript between the Abstract (if applicable) and the Introduction, and should be 150-200 words long. The aim should be to make your findings accessible to a wide audience that includes both scientists and non-scientists. Sample summaries can be found on our website under Submission Guidelines:

https://journals.plos.org/plosntds/s/submission-guidelines#loc-parts-of-a-submission

3) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines:

https://journals.plos.org/plosntds/s/figures

4) We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list.

5) We note that your Data Availability Statement is currently as follows: "The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.". Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis..

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

Reviewers' comments: Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: The objectives are clear and they have been achieved. Some comments:

"OROV is an acute febriel disease..." should be replaced by "OROV causes an acute febriel disease..." as OROV is the virus, nor the disease.

There is not and evident lack of literature; there is an evident lack of systematic review of the scattered data. So, better reformulate the sentence... "To date, the comprehensive.... as ther is an evident lack of systematic reviews."

Why does this lower limit of studies of less than five cases make these studies ineligible? They keep adding cases to the final "n".

What meaning do the numbers 5 and 8 have next to Peru and Brazil, respectively, in Table 1? No information about this appears in the table key.

The phrase...."The prominence of ocular involvement, particularly retro-orbital pain, photophobia, and red eyes." lacks a clear meaning for me. It seems that the verb is missing.

Remember that most taxonomic names are in italics. Check references 10, 16.

Reviewer #2: Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

Yes, the objectives of the study are clearly articulated. The study aims to systematically review and meta-analyze the clinical presentation of Oropouche virus (OROV) infection. The hypothesis is implied rather than explicitly stated, but the study seeks to provide a comprehensive understanding of the clinical manifestations of OROV infection, which is a clear and testable objective.

Is the study design appropriate to address the stated objectives?

Yes, the study design is appropriate. The authors conducted a systematic review and meta-analysis, which is suitable for summarizing the clinical manifestations of OROV infection across multiple studies. The inclusion and exclusion criteria are well-defined, and the search strategy is comprehensive.

Is the population clearly described and appropriate for the hypothesis being tested?

Yes, the population is clearly described. The study includes 806 patients from 15 studies, all of whom were confirmed to have OROV infection via PCR or ELISA. The population is appropriate for the hypothesis being tested, as it focuses on individuals with confirmed OROV infection.

Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

Yes, the sample size of 806 patients from 15 studies is sufficient for a meta-analysis. The authors have included a reasonable number of studies and patients to ensure adequate power to address the hypothesis.

Were correct statistical analyses used to support conclusions?

Yes, the statistical analyses appear to be appropriate. The authors used a fixed-effect model for meta-analysis and assessed heterogeneity using the I² statistic. They also used forest plots and funnel plots to visualize the data and assess publication bias. The methods are well-described and appropriate for the type of data being analyzed.

Are there concerns about ethical or regulatory requirements being met?

No, there are no apparent concerns about ethical or regulatory requirements. The study is a systematic review and meta-analysis of previously published studies, so it does not involve direct human or animal subjects. The authors have declared no competing interests and no specific funding for this work.

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: Appropriate and sufficient. If the quality and disaggregation of the clinical data in the different studies allowed it, a review of the clinical presentations by age or sex would have been interesting to read.

Reviewer #2: Does the analysis presented match the analysis plan?

Yes, the analysis presented matches the analysis plan outlined in the methods section. The authors conducted a meta-analysis of clinical symptoms and presented the results in a clear and structured manner.

Are the results clearly and completely presented?

Yes, the results are clearly and completely presented. The authors provide detailed tables and figures summarizing the prevalence of various symptoms, including general, gastrointestinal, ocular, respiratory, and skin-related symptoms. The results are well-organized and easy to follow.

Are the figures (Tables, Images) of sufficient quality for clarity?

Yes, the figures and tables are of sufficient quality for clarity. The forest plots and tables are well-constructed and provide a clear visual representation of the data. The figures are appropriately labeled and easy to interpret.

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The conclusion are supported by the data presented. Limitations of the analysis are clearly described but not completely assessed. Taking into account that the circulation of this virus basically occurs in Latin America, how many studies in Spanish or Portuguese/Brazilian have been not considered and therefore discarded? How many cases? What impact does this selection have on the final result?

The discussion is sufficient and obviously it has public health relevance for the professionals in the field.

Reviewer #2: Are the conclusions supported by the data presented?

Yes, the conclusions are supported by the data presented. The authors conclude that OROV infection presents with a wide range of symptoms, including fever, headache, gastrointestinal disturbances, ocular symptoms, and respiratory symptoms. These conclusions are well-supported by the meta-analysis results.

Are the limitations of analysis clearly described?

Yes, the limitations of the analysis are clearly described. The authors acknowledge that most of the included studies were retrospective and that there may be publication bias due to the exclusion of asymptomatic or mild cases. They also note the potential for selection bias and the lack of high-quality data in some studies.

Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

Yes, the authors discuss the public health relevance of their findings. They emphasize the need for heightened clinical awareness and a comprehensive approach to patient evaluation, which can help in the accurate diagnosis and management of OROV infection. This discussion is relevant and adds value to the study.

Is public health relevance addressed?

Yes, the public health relevance is addressed. The authors highlight the increasing incidence and geographic spread of OROV infections and the need for targeted public health interventions. They also discuss the importance of integrating ophthalmologic evaluations into the management protocol for suspected OROV cases.

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: This reviewer believes that a new reading of the text and improving the constructions of some sentences would improve the manuscript.

Reviewer #2: The authors should consider explicitly stating the hypothesis in the introduction to make the study's objectives even clearer.

The discussion could be strengthened by comparing the findings with other arboviral infections (e.g., dengue, Zika) in more detail, as this would provide additional context for the clinical significance of OROV symptoms.

The authors should ensure that all abbreviations are defined upon first use (e.g., "OROV" is defined, but other abbreviations like "PCR" and "ELISA" are not).

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: This is a systematic review of the clinical symptoms of Oropouche virus infection based on previous work. Systematizes dispersed data and organizes it. Useful for case management and public health.

Reviewer #2: Strengths:

The study is well-designed and addresses an important gap in the literature regarding the clinical presentation of OROV infection.

The meta-analysis is conducted rigorously, with appropriate statistical methods and clear presentation of results.

The study has significant public health relevance, particularly in regions where OROV is endemic or emerging.

Weaknesses:

The study is limited by the retrospective nature of most included studies and potential publication bias, as acknowledged by the authors.

The discussion could be expanded to provide more context on how OROV symptoms compare to other arboviral infections, which would enhance the study's clinical relevance.

Novelty and Significance:

This is the first systematic review and meta-analysis to comprehensively summarize the clinical manifestations of OROV infection. The findings are novel and provide a foundational understanding that can guide future research and public health interventions.

General Execution and Scholarship:

The study is well-executed and demonstrates a high level of scholarship. The authors have followed appropriate guidelines for systematic reviews and meta-analyses, and the manuscript is well-written and organized.

PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]Figure resubmission:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions.

 Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012962.r004

Decision Letter 1

Elvina Viennet

4 Mar 2025

Dear Dr Li,

We are pleased to inform you that your manuscript 'Clinical presentation of Oropouche virus infection: a systematic review and meta-analysis' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Adly M.M. Abd-Alla, Prof asso.

Academic Editor

PLOS Neglected Tropical Diseases

Elvina Viennet

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

***********************************************************

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012962.r005

Acceptance letter

Elvina Viennet

Dear Dr Li,

We are delighted to inform you that your manuscript, "Clinical presentation of Oropouche virus infection: a systematic review and meta-analysis," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data. Original data of OROV-infected patients included in the study.

    (XLSX)

    pntd.0012962.s001.xlsx (18.4KB, xlsx)
    S1 Checklist. PRISMA 2020 Checklist.

    (DOCX)

    pntd.0012962.s002.docx (30.6KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pntd.0012962.s004.docx (26.5KB, docx)

    Data Availability Statement

    All relevant data are in the manuscript and its supporting information files.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES